Alert: Canvas Outage
CU is aware that Canvas is unavailable and the webpage temporarily displayed a message regarding a security breach of Canvas. The site is now displaying a maintenance message. CU is working with the vendor to investigate and resolve the issue. CU does not control the platform. We cannot provide a timeline for resolution. This incident is impacting Canvas instances globally and is part of the larger data breach reported to you on Monday. We will provide additional updates as they are available.
CU is aware that Canvas is unavailable and the webpage temporarily displayed a message regarding a security breach of Canvas. The site is now displaying a maintenance message. CU is working with the vendor to investigate and resolve the issue. CU does not control the platform. We cannot provide a timeline for resolution. This incident is impacting Canvas instances globally and is part of the larger data breach reported to you on Monday. We will provide additional updates as they are available.
Learn More
Kimberly Muller
Vice Chancellor for Innovation and Biotechnology
Biography
Kimberly
Muller is the Vice Chancellor for Innovation and Biotechnology and Executive Director of CU Anschutz Innovations, where she leads innovation for the campus. Kimberly’s business development responsibilities include investing, company creation, innovation management,
forming key strategic industry partnerships, and licensing. Large-scale industry collaborations have been established in areas such as AI and drug development. She also manages several investment funds, including a $10 million innovation grant fund,
a $50 million early-stage venture fund, a $75 million follow-on fund, and partners with UCHealth on a $100 million growth stage fund.
Kimberly joined the University of Colorado from Yale University where she was formerly the Deputy Director of the Yale Entrepreneurial Institute (YEI), and managed New Ventures in the Office of Cooperative Research. During Kimberly’s tenure, Yale’s Office of Cooperative Research started more than 70 new ventures that have raised over $5 billion in investor capital.
Previously, Kimberly started and sold companies in the biotech, tech, and clean energy fields, companies included Curagen Corporation (acquired by Celldex Therapeutics), 454 Life Science (acquired by Roche), and Arbor Fuel, a biofuel company that utilized recombinant microorganisms for the production of ethanol and butanol. Kimberly began her career in New York as a patent attorney for Chadbourne and Parke, LLP.
Kimberly has a graduate degree in Genetics and received her law degree with highest honors from the University of Connecticut School of Law.
CU Anschutz Innovations Website